Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
| Market Cap | 20.19M | P/E | - | EPS this Y | 95.60% | Ern Qtrly Grth | - |
| Income | -32.8M | Forward P/E | -2.26 | EPS next Y | - | 50D Avg Chg | -94.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -96.00% |
| Dividend | N/A | Price/Book | 0.05 | EPS next 5Y | - | 52W High Chg | -97.00% |
| Recommedations | 3.00 | Quick Ratio | 5.99 | Shares Outstanding | 19.04M | 52W Low Chg | - |
| Insider Own | 6.28% | ROA | -40.60% | Shares Float | 0.91M | Beta | 0.48 |
| Inst Own | 37.18% | ROE | -81.72% | Shares Shorted/Prior | 2.42M/1.54M | Price | 1.06 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 140,504 | Target Price | 2.00 |
| Oper. Margin | - | Earnings Date | Nov 9 | Volume | 1,912,625 | Change | -5.36% |
About Millendo Therapeutics, Inc.
As of June 25, 2021, Millendo Therapeutics, Inc. was acquired by Tempest Therapeutics Inc., in a reverse merger transaction. Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan.